EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Neurological Adverse Events Associated With Immune Checkpoint Inhibitors Identified Through Disproportionality Analysis of the FDA Adverse Event Reporting System

Tao Chen, Kexin Shu iD, Hongyi Xiao iD, Yonghua Yuan iD, Fujun Zhang iD, Yu Liu iD

Cancer Medicine · 2026

DOI: 10.1002/cam4.72206 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, 2026. Verfasst von Tao Chen und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Adverse Drug Reaction Reporting Systems, Nervous System Diseases, Drug-Related Side Effects and Adverse Reactions. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Chongqing Medical University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Neurological immune‐related adverse events (N‐irAEs) from immune checkpoint inhibitors (ICIs) are rare but potentially fatal. This study aimed to characterize their real‐world profile to support early detection and management.

Methods

We analyzed ICI‐associated individual case safety reports (ICSRs) in the FDA Adverse Event Reporting System (FAERS) from April 2011 to June 2023. Disproportionality analyses used the reporting odds ratio (ROR) and the Bayesian confidence propagation neural network (BCPNN). Associations between serious N‐irAEs and sex or age group (< 60 vs. ≥ 60 years) were assessed using chi‐squared tests. We also evaluated the co‐occurrence of myasthenia gravis with myositis and/or myocarditis and its association with mortality.

Results

A total of 3486 ICSRs involving N‐irAEs were identified, with 550 cases reporting fatal outcomes. A total of 4139 N‐irAE signals were detected; among these, 2560 signals corresponded to the top 10 Preferred Terms (PTs) with the highest reporting frequencies. The median time from ICI initiation to the onset of N‐irAEs was 82 days (IQR: 29–219 days). Of the 4139 N‐irAE signals, 1925 (46.5%) were classified as serious adverse events; no statistically significant differences were observed in their distribution by sex ( χ 2 = 2.492, p = 0.114) or age ( χ 2 = 2.946, p = 0.086). A total of 461 cases of myasthenia gravis were identified, of which 219 (47.5%) were concomitant with myocarditis and/or myositis. Among the 137 fatal cases of myasthenia gravis, 70 (51.1%) were concomitant with myocarditis and/or myositis.

Conclusion

This study offers a comprehensive characterization of N‐irAEs, highlights the fatality risk when myasthenia gravis co‐occurs with myocarditis and/or myositis, and underscores the importance of early recognition, multi‐system evaluation, and timely intervention to improve patient safety and optimize the risk–benefit balance of immunotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immune Checkpoint InhibitorsAdverse Drug Reaction Reporting SystemsNervous System DiseasesDrug-Related Side Effects and Adverse ReactionsNeoplasmsHumansFemaleUnited StatesMaleUnited States Food and Drug AdministrationMiddle AgedAgedMyasthenia GravisMyocarditisMyositisBayes Theorem

Stichwörter der Autor:innen

FAERS databasedata miningdisproportionality analysisimmune checkpoint inhibitorsneurological adverse events

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Pharmacy, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
  • Chongqing Medical University, Chongqing, China.
  • Department of Oral and Maxillofacial Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
  • College of Pharmacy, Chongqing Medical University, Chongqing, China.

ORCID-Profile: Kexin Shu, Hongyi Xiao, Yonghua Yuan, Fujun Zhang, Yu Liu

Förderung

  • Chongqing Medical University

Zitieren

APA

Chen, T., Shu, K., Xiao, H., Yuan, Y., Zhang, F., & Liu, Y. (2026). Neurological Adverse Events Associated With Immune Checkpoint Inhibitors Identified Through Disproportionality Analysis of the FDA Adverse Event Reporting System. Cancer Medicine. https://doi.org/10.1002/cam4.72206

Vancouver

Chen T, Shu K, Xiao H, Yuan Y, Zhang F, Liu Y. Neurological Adverse Events Associated With Immune Checkpoint Inhibitors Identified Through Disproportionality Analysis of the FDA Adverse Event Reporting System. Cancer Medicine. 2026. doi:10.1002/cam4.72206

BibTeX
@article{Chen2026,
  author = {Chen, Tao and Shu, Kexin and Xiao, Hongyi and Yuan, Yonghua and Zhang, Fujun and Liu, Yu},
  title = {Neurological Adverse Events Associated With Immune Checkpoint Inhibitors Identified Through Disproportionality Analysis of the FDA Adverse Event Reporting System},
  journal = {Cancer Medicine},
  year = {2026},
  doi = {10.1002/cam4.72206}
}
Kostenlos starten →